1. Use of Infliximab in the Treatment of Macrophage Activation Syndrome Complicating Kawasaki Disease.
- Author
-
Rivera-Rodriguez L, Pardo-Díaz E, Moreno-Espinosa S, Scheffler-Mendoza S, Ruiz-Ontiveros MA, Garrido-García LM, Iglesias-Amaya A, and Yamazaki-Nakashimada MA
- Subjects
- Adrenal Cortex Hormones therapeutic use, Adult, Child, Preschool, Cyclosporine therapeutic use, Female, Humans, Immunoglobulins, Intravenous therapeutic use, Macrophage Activation Syndrome complications, Male, Mucocutaneous Lymph Node Syndrome complications, Young Adult, Dermatologic Agents therapeutic use, Infliximab therapeutic use, Macrophage Activation Syndrome drug therapy, Mucocutaneous Lymph Node Syndrome drug therapy
- Abstract
Kawasaki disease (KD) is an acute systemic vasculitis of unknown etiology. KD can be complicated with macrophage activation syndrome. The optimal treatment for this KD complication has not been established, and a variety of treatments have been used. Infliximab, a chimeric monoclonal antibody that binds tumor necrosis factor, has proved to be efficacious in IV gammaglobulin resistant KD. We present 2 cases of KD complicated with macrophage activation syndrome, including 1 patient with DiGeorge syndrome successfully treated with a combined treatment of IV gammaglobulin, corticosteroids, cyclosporine, and infliximab., Competing Interests: The authors declare no conflict of interest., (Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF